Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism

European Journal of Endocrinology

Volumn 168, Issue 1, 2013, Pages 75-81

  Fourkiotis, Verena ^a   Vonend, Oliver ^b   Diederich, Sven ^c   Fischer, Evelyn ^d   Lang, Katharina ^e   Endres, Stephan ^d   Beuschlein, Felix ^d   Willenberg, Holger S ^b   Rump, Lars C ^b   Allolio, Bruno ^e   Reincke, Martin ^d   Quinkler, Marcus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Department of Orthopedic Surgery   (Germany)

^c Endokrinologikum Berlin   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; CREATININE; EPLERENONE; POTASSIUM; SPIRONOLACTONE;

ADRENALECTOMY; ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BREAST TENDERNESS; COHORT ANALYSIS; CREATININE URINE LEVEL; CROSS-SECTIONAL STUDY; DRUG EFFICACY; FEMALE; GLOMERULUS FILTRATION RATE; GYNECOMASTIA; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; MULTICENTER STUDY; POTASSIUM BLOOD LEVEL; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; TREATMENT OUTCOME; URINARY EXCRETION;

ADRENALECTOMY; ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; BLOOD PRESSURE; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERALDOSTERONISM; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SPIRONOLACTONE;

EID: 84871948789     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0631     Document Type: Article

References (44)

1. Quinkler M & Stewart PM. Treatment of primary aldosteronism. Best Practice and Research. Clinical Endocrinology and Metabolism 2010 24 923-932. (doi:10.1016/j.beem.2010.10.001)
2. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R, Allolio B, Seufert J, Schirpenbach C, Beuschlein F et al. Cardio- and cerebrovascular comorbidites of hypo- and normokalemic primary aldosteronism: results of the German Conn's Registry. Journal of Clinical Endocrinology and Metabolism 2009 94 1125-1130. (doi:10.1210/jc.2008-2116)
3. Reincke M, Rump LC, Quinkler M, Hahner S, Diederich S, Lorenz R, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 2009 94 869-875. (doi:10.1210/jc.2008- 1851)
4. Rossi GP. Primary aldosteronism: a needle in a haystack or a yellow cab on fifth avenue? Current Hypertension Reports 2004 6 1-4. (doi:10.1007/s11906- 004-0001-0)
5. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Matterello MJ et al. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension 2006 48 232-238. (doi:10.1161/01.HYP.0000230444.01215.6a)
6. Born-Frontsberg E, Reincke M, Beuschlein F & Quinkler M. Tumor size of Conn's adenoma and comorbidities. Hormone and Metabolic Research 2009 41 785-788. (doi:10.1055/s-0029-1224200)
7. Quinkler M, Born-Frontsberg E & Fourkiotis VG. Comorbidities in primary aldosteronism. Hormone and Metabolic Research 2010 42 429-434. (doi:10.1055/s-0029-1243257)
8. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME & Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. Journal of the American College of Cardiology 2005 45 1243-1248. (doi:10.1016/j.jacc.2005.01.015)
9. Halimi JM & Mimran A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. Journal of Hypertension 1995 13 1801-1802. (Pubitemid 26015820)
10. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL & Catena C. Long-term renal outcomes in patients with primary aldosteronism. Journal of the American Medical Association 2006 295 2638-2645. (doi:10.1001/jama.295.22.2638)
11. Ribstein J, Du Cailar G, Fesler P & Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. Journal of the American Society of Nephrology 2005 16 1320-1325. (doi:10.1681/ASN.2004100878)
12. Catena C, Colussi G, Di Fabio A, Valeri M, Marzano L, Uzzau A & Sechi LA. Mineralocorticoid antagonists treatment versus surgery in primary aldosteronism. Hormone and Metabolic Research 2010 42 440-445. (doi:10.1055/s-0029-1246185)
13. Sechi LA, Colussi G, Di Fabio A & Catena C. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. American Journal of Hypertension 2010 23 1253-1260. (doi:10.1038/ajh.2010.169)
14. Quinkler M, Zehnder D, Eardley KS, Lepenies J, Howie AJ, Hughes SV, Cockwell P, Hewison M & Stewart PM. Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria. Circulation 2005 112 1435-1443. (doi:10.1161/CIRCULATIONAHA.105. 539122)
15. Lam EY, Funder JW, Nikolic-Paterson DJ, Fuller PJ & Young MJ. Mineralocorticoid receptor blockade but not steroid withdrawal reverses renal fibrosis in deoxycorticosterone/salt rats. Endocrinology 2006 147 3623-3629. (doi:10.1210/en.2005-1527)
16. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML & McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney International 2003 63 1791-1800. (doi:10.1046/j.1523-1755.2003.00929.x)
17. Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E & Ishibashi S. Spironolactone prevents early renal injury in streptozotocin- induced diabetic rats. Kidney International 2004 66 1493-1502. (doi:10.1111/j.1523-1755.2004.00913.x)
18. Sun GP, Kohno M, Guo P, Nagai Y, Miyata K, Fan YY, Kimura S, Kiyomoto H, Ohmori K, Li DT et al. Involvements of rho-kinase and TGF-b pathways in aldosterone-induced renal injury. Journal of the American Society of Nephrology 2006 17 2193-2201. (doi:10.1681/ASN.2005121375)
19. Toyonaga J, Tsuruya K, Ikeda H, Noguchi H, Yotsueda H, Fujisaki K, Hirakawa M, Taniguchi M, Masutani K & Iida M. Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. Nephrology, Dialysis, Transplantation 2011 26 2475-2484. (doi:10.1093/ndt/gfq750)
20. Chen C, Liang W, Jia J, van Goor H, Singhal PC & Ding G. Aldosterone induces apoptosis in rat podocytes: role of PI3-K/Akt and P38MAPK signaling pathways. Nephron. Experimental Nephrology 2009 113 e26-e34. (doi:10.1159/000228080)
21. Reincke M, Meisinger C, Holle R, Quinkler M, Hahner S, Beuschlein F, Bidlingmaier M, Seissler J & Endres S. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn's Registry. Hormone and Metabolic Research 2010 42 435-439. (doi:10.1055/s-0029-1246189)
22. Fischer E, Beuschlein F, Bidlingmaier M & Reincke M. Commentary on the Endocrine Society Practice Guidelines: consequences of adjustment of antihypertensive medication in screening of primary aldosteronism. Reviews in Endocrine & Metabolic Disorders 2011 12 43-48. (doi:10.1007/s11154-011-9163- 7)
23. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T et al. A new equation to estimate glomerular filtration rate. Annals of Internal Medicine 2009 150 604-612.
24. Botev R, Mallie JP, Wetzels JF, Couchoud C & Schuck O. The clinician and estimation of glomerular filtration rate by creatinine-based formulas: current limitations and Quo Vadis. Clinical Journal of the American Society of Nephrology 2011 6 937-950. (doi:10.2215/CJN.09241010)
25. Funder J, Carey R, Fardella C, Gomez-Sanchez C, Mantero F, Stowasser M, Young W & Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism 2008 93 3266-3281. (doi:10.1210/jc.2008-0104)
26. Vonend O, Ockenfels N, Gao X, Allolio B, Lang K, Mai K, Quack I, Saleh A, Degenhart C, Seufert J et al. Adrenal venous sampling: evaluation of the German Conn's Registry. Hypertension 2011 57 990-995. (doi:10.1161/HYPERTENSIONAHA. 110.168484)
27. Mehdi UF, Adams-Huet B, Raskin P, Vega GL & Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. Journal of the American Society of Nephrology 2009 20 2641-2650. (doi:10.1681/ASN.2009070737)
28. Sato A, Hayashi K, Naruse M & Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003 41 64-68. (doi:10.1161/01.HYP.0000044937.95080.E9)
29. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P & Parving HH. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney International 2006 70 536-542. (Pubitemid 44141580)
30. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R & Beckerman B. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clinical Journal of the American Society of Nephrology 2006 1 940-951. (doi:10.2215/CJN.00240106)
31. Epstein M. Aldosterone receptor blockade and the role of eplerenone: evolving perspectives. Nephrology, Dialysis, Transplantation 2003 18 1984-1992. (doi:10.1093/ndt/gfg339)
32. Bianchi S, Bigazzi R & Campese VM. Antagonists of aldosterone and proteinuria in patients With CKD: an uncontrolled pilot study. American Journal of Kidney Diseases 2005 46 45-51. (doi:10.1053/j.ajkd.2005.03.007)
33. Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E & Shoji T. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin- converting enzyme inhibitor and angiotensin II receptor blocker. Hypertension Research 2008 31 59-67. (doi:10.1291/hypres.31.59)
34. Fourkiotis VG, Hanslik G, Hanusch F, Lepenies J & Quinkler M. Aldosterone and the kidney. Hormone and Metabolic Research 2012 44 194-201. (doi:10.1055/s-0031-1295461)
35. Briet M & Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nature Reviews. Nephrology 2010 6 261-273. (doi:10.1038/nrneph.2010.30)
36. Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T & Kimura G. Cardiovascular complications in patients with primary aldosteronism. American Journal of Kidney Diseases 1999 33 261-266. (doi:10.1016/S0272-6386(99) 70298-2)
37. Wu VC, Yang SY, Lin JW, Cheng BW, Kuo CC, Tsai CT, Chu TS, Huang KH, Wang SM, Lin YH et al. Kidney impairment in primary aldosteronism. Clinica Chimica Acta 2011 412 1319-1325. (doi:10.1016/j.cca.2011.02.018)
38. Wu VC, Kuo CC, Wang SM, Liu KL, Huang KH, Lin YH, Chu TS, Chang HW, Lin CY, Tsai CT et al. Primary aldosteronism: changes in cystatin C-based kidney filtration, proteinuria, and renal duplex indices with treatment. Journal of Hypertension 2011 29 1778-1786. (doi:10.1097/HJH.0b013e3283495cbb)
39. Sechi LA, Di Fabio A, Bazzocchi M, Uzzau A & Catena C. Intrarenal hemodynamics in primary aldosteronism before and after treatment. Journal of Clinical Endocrinology and Metabolism 2009 94 1191-1197. (doi:10.1210/jc.2008- 2245)
40. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R & Sechi LA. Relationships of plasma renin levels with renal function in patients with primary aldosteronism. Clinical Journal of the American Society of Nephrology 2007 2 722-731. (doi:10.2215/CJN.00050107)
41. Karagiannis A, Tziomalos K, Papageorgiou A, Kakafika AI, Pagourelias ED, Anagnostis P, Athyros VG & Mikhailidis DP. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. Expert Opinion on Pharmacotherapy 2008 9 509-515. (doi:10.1517/14656566.9.4.509)
42. Parthasarathy HK, Menard J, White WB, Young WF Jr, Williams GH, Williams B, Ruilope LM, McInnes GT, Connell JM & MacDonald TM. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. Journal of Hypertension 2011 29 980-990. (doi:10.1097/HJH. 0b013e3283455ca5)
43. Hofmann PJ, Michaelis M, Gotz F, Bartel C, Kienitz T & Quinkler M. Flutamide increases aldosterone levels in gonadectomized male but not female Wistar rats. American Journal of Hypertension 2012 25 697-703. (doi:10.1038/ajh.2012.21)
44. Michaelis M, Hofmann PJ, Gotz F, Bartel C, Kienitz T & Quinkler M. Sex-specific effects of spironolactone on blood pressure in gonadectomized male and female Wistar rats. Hormone and Metabolic Research 2012 44 291-295. (doi:10.1055/s-0031-1299774)